Performance Characteristics of the TRUGENE
HIV-1
Genotyping Kit and the Opengene DNA Sequencing System
-
Published:2003-04
Issue:4
Volume:41
Page:1594-1599
-
ISSN:0095-1137
-
Container-title:Journal of Clinical Microbiology
-
language:en
-
Short-container-title:J Clin Microbiol
Author:
Kuritzkes Daniel R.1, Grant Robert M.2, Feorino Paul3, Griswold Marshal4, Hoover Marie5, Young Russell1, Day Stephen3, Lloyd, Robert M.3, Reid Caroline6, Morgan Gillian F.6, Winslow Dean L.6
Affiliation:
1. Division of Infectious Diseases, University of Colorado Health Sciences Center, Denver, Colorado 2. Gladstone Institute of Virology and Immunology, San Francisco 3. Visible Genetics, Inc., Suwanee, Georgia 4. Consolidated Laboratories, Van Nuys, California 5. Advanced BioMedical Laboratories, Cinnaminson, New Jersey 6. Visible Genetics, Inc., Toronto, Ontario, Canada
Abstract
ABSTRACT
The TRUGENE
HIV-1
Genotyping Kit and OpenGene DNA Sequencing System are designed to sequence the protease (PR)- and reverse transcriptase (RT)-coding regions of human immunodeficiency virus type 1 (HIV-1)
pol
. Studies were undertaken to determine the accuracy of this assay system in detecting resistance-associated mutations and to determine the effects of RNA extraction methods, anticoagulants, specimen handling, and potentially interfering substances. Samples were plasma obtained from HIV-infected subjects or seronegative plasma to which viruses derived from wild-type and mutant infectious molecular clones (IMC) of HIV-1 were added. Extraction methods tested included standard and UltraSensitive AMPLICOR HIV-1 MONITOR, QIAGEN viral RNA extraction mini kit, and QIAGEN Ultra HIV extraction kit, and NASBA manual HIV-1 quantitative NucliSens. Sequence data from test sites were compared to a “gold standard” reference sequence to determine the percent agreement. Comparisons between test and reference sequences at the nucleotide level showed 97.5 to 100% agreement. Similar results were obtained regardless of extraction method, regardless of use of EDTA or acid citrate dextrose as anticoagulant, and despite the presence of triglycerides, bilirubin, hemoglobin, antiretroviral drugs, HIV-2, hepatitis C virus (HCV), HBV, cytomegalovirus, human T-cell leukemia virus type 1 (HTLV-1), or HTLV-2. Samples with HIV-1 RNA titers of ≥1,000 copies/ml gave consistent results. The TRUGENE
HIV-1
Genotyping Kit and OpenGene DNA Sequencing System consistently generate highly accurate sequence data when tested with IMC-derived HIV and patient samples.
Publisher
American Society for Microbiology
Subject
Microbiology (medical)
Reference17 articles.
1. Baxter J. D. D. L. Mayers D. N. Wentworth J. D. Neaton M. L. Hoover M. A. Winters S. B. Mannheimer M. A. Thompson D. I. Abrams B. J. Brizz J. P. A. Ioannidis T. C. Merigan and the CPCRA 046 Study Team for the Terry Berin Community Programs for Clinical Research on AIDS (CPCRA). 2000. A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy. AIDS 14: F83-F93. 2. Cohen, C. J., M. Sension, C. Farthing, M. Conant, S. Jacobson, J. Nadler, W. Verbiest, K. Hertogs, M. Ames, A. Rinehart, N. M. Graham, and the VIRA 3001 Study Team. 2002. A randomized trial assessing the Impact of phenotypic resistance testing on antiretroviral therapy. AIDS16:1-10. 3. D'Aquila, R. T., V. A. Johnson, S. L. Welles, A. J. Japour, D. R. Kuritzkes, V. DeGruttola, P. S. Reichelderfer, R. W. Coombs, C. S. Crumpacker, J. O. Kahn, and D. D. Richman for the AIDS Clinical Trials Group 116B/117 Team, and the Virology Committee Resistance Working Group. 1995. Zidovudine resistance and human immunodeficiency virus type 1 disease progression during antiretroviral therapy. Ann. Intern. Med.122:401-408. 4. Deeks, S. G., N. S. Hellmann, R. M. Grant, N. T. Parkin, C. J. Petropoulos, M. Becker, W. Symonds, M. Chesney, and P. A. Volberding. 1999. Novel four-drug salvage treatment regimens after failure of HIV-1 protease inhibitor-containing regimen: antiviral activity and correlation of baseline phenotypic drug susceptibility. J. Infect. Dis.179:1375-1381. 5. DeGruttola, V., L. Dix, R. D'Aquila, D. Holder, A. N. Phillips, M. Ait-Khaled, J. D. Baxter, P. Clevenbergh, S. Hammer, R. P. Harrigan, D. Katzenstein, R. Lanier, M. D. Miller, M. Para, S. Yerly, A. R. Zolopa, J. S. Murray, A. Patick, V. Miller, S. Castillo, L. Pedneault, and J. Mellors. 2000. The relation between baseline HIV drug resistance and response to antiretroviral therapy: re-analysis of retrospective and prospective studies using a standardized data analysis plan. Antivir. Ther.5:41-48.
Cited by
66 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|